Goldman Sachs
SGMT icon

Goldman Sachs’s Sagimet Biosciences SGMT Stock Holding History

Goldman Sachs’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.87M Buy
759,086
+589,827
+348% +$4.01M ﹤0.01% 3747
2026
Q1 		$884K Buy
169,259
+43,313
+34% +$241K ﹤0.01% 5176
2025
Q4 		$746K Buy
125,946
+110,754
+729% +$796K ﹤0.01% 5343
2025
Q3 		$104K Sell
15,192
-3,429
-18% -$27.8K ﹤0.01% 6071
2025
Q2 		$142K Sell
18,621
-4,982
-21% -$21K ﹤0.01% 5750
2025
Q1 		$76.9K Sell
23,603
-109,464
-82% -$459K ﹤0.01% 5831
2024
Q4 		$599K Buy
133,067
+348
+0.3% +$1.76K ﹤0.01% 5138
2024
Q3 		$368K Sell
132,719
-129,369
-49% -$399K ﹤0.01% 5208
2024
Q2 		$896K Buy
262,088
+232,342
+781% +$1.07M ﹤0.01% 4480
2024
Q1 		$161K Buy
+29,746
New +$214K ﹤0.01% 5168
2023
Q4 		– Sell
-19,654
Closed -$173K – 5817
2023
Q3 		$173K Buy
+19,654
New +$262K ﹤0.01% 5077

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Goldman Sachs's SGMT Position: Q2 2026 in Review

Goldman Sachs increased its Sagimet Biosciences (SGMT) stake by 348% in Q2 2026, buying an estimated $4.01M and bringing the position to 759,086 shares worth $5.87M. The position accounts for ﹤0.01% of the portfolio, ranked #3747.

Goldman Sachs first reported a position in SGMT in Q3 2023 and has held it in 11 quarters since. 122 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Goldman Sachs held 759,086 shares of Sagimet Biosciences worth $5.87M as of Q2 2026.
  • Goldman Sachs bought 589,827 Sagimet Biosciences shares in Q2 2026, an estimated $4.01M.
  • Sagimet Biosciences made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3747 holding.
  • Goldman Sachs first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 11 quarters since.
  • 122 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.